Severe Acute Respiratory Syndrome 2 (SARS-CoV-2)

The new Roche SARS-CoV-2 antibody assay has received FDA EUA for qualitative and semiquantitative detection of antibodies to the SARS-CoV-2 spike (S) protein’s receptor binding domain. Positive results indicate the development of active immunity after vaccination. Please be advised that Boston Heart Diagnostics policy states that practitioners cannot order labs on themselves or their immediate family members.

This test looks for antibodies that indicate a recent or prior infection with COVID-19.

The new Siemens COVID-19 test assays for the spike 1 protein neutralizing antibodies, which prevents viral penetration into the cell. Clinical Specificity: 100% Clinical Sensitivity: 99.95%

This test looks for antibodies that indicate a recent or prior infection with COVID-19. This test should only be done for patients that are 15 days or more post-symptom onset.

This is a single-marker TaqPath COVID-19 (SARS-CoV-2) NP swab test measuring COVID-19 RNA. It helps determine whether or not a patient has contracted COVID-19. Please be advised that Boston Heart Diagnostics policy states that practitioners cannot order labs on themselves or their immediate family members.